Chester County News and Community Website
Ocugen, Inc. (NASDAQ: OCGN), headquartered in Malvern, PA, is a biopharmaceutical company focused on discovering, developing, and commercializing transformative therapies to cure blindness diseases. Their breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with one drug – “one to many” and their novel biologic product candidate aims to offer better therapy to patients with underserved diseases such as wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy. For more information, visit www.ocugen.com.
MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) announced progress in its Phase 1 clinical trial for OCU200, a novel biologic designed to treat diabetic macular edema (DME) and related eye conditions. …
Ocugen Advances OCU200 Clinical Trial Amid Promising Safety Results Read More MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) has reported its fourth-quarter and full-year 2024 financial results, alongside significant progress across its clinical programs and regulatory initiatives. The company continues to drive …
Ocugen Reports 2024 Financial Results and Advances Gene Therapy Programs Read More MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) announced that the European Commission has granted Advanced Therapy Medicinal Product (ATMP) classifications for its gene therapies OCU410 and OCU410ST. This regulatory milestone …
Ocugen Secures ATMP Classification for Gene Therapies Targeting Vision Loss Read More MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) announced a significant milestone with the U.S. Food and Drug Administration (FDA), gaining alignment to advance its Phase 2/3 pivotal confirmatory trial of OCU410ST, …
FDA Greenlights Ocugen’s Breakthrough Gene Therapy Trial, Offering New Hope for Stargardt Disease Patients Read More MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) has announced that it will host a conference call and live webcast to discuss its fourth quarter and full-year 2024 financial results, along …
Ocugen to Announce Q4 and Full-Year 2024 Results with Live Webcast on March 5, 2025 Read More MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) has announced the completion of dosing in the Phase 2 portion of its ArMaDa clinical trial for OCU410. This novel multifunctional modifier gene therapy …
Breakthrough Gene Therapy OCU410 Could Save Millions from Vision Loss – Phase 2 Milestone Achieved! Read More MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) has reached a significant milestone in the development of its gene-agnostic therapy, OCU400, as the European Commission has delivered a positive opinion designating it …
Ocugen’s OCU400 Receives ATMP Classification from European Commission, Advancing Retinitis Pigmentosa Treatment Read More MALVERN, PA — Biopharmaceutical company Ocugen, Inc. (NASDAQ: OCGN) has announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for OCU500, a novel …
Ocugen Receives FDA Greenlight for Phase 1 Trial of Mucosal COVID-19 Vaccine Read More MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) this week announced the dosing of the first patient in its Phase 1 clinical trial for OCU200, a potential treatment for diabetic macular edema …
Breakthrough in Sight? Ocugen’s OCU200 Targets Vision Loss for Millions in New Clinical Trial Read More MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) has announced a positive 2-year safety and efficacy update from its Phase 1/2 clinical trial for OCU400, a groundbreaking gene therapy targeting retinitis pigmentosa …
Breakthrough in Vision: Ocugen’s OCU400 Shows Promising 2-Year Results for Retinitis Pigmentosa Read More